Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19

NCT04568096 is registered in ClinicalTrials.gov with Kafrelsheikh University as lead sponsor.

NCT NCT04568096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04568096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19
Lead sponsor
Kafrelsheikh University
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2020
Completion date
December 31, 2020
Enrollment
160 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

the lung complication of covid-19